Our database was recently updated with more Horizon Europe new calls for research on Health that you should check out. Are you a researcher or a research organisation in the field of Health and health care looking for EU funding for your next research project on Health? Then, look no further than Horizon Europe as this is the funding programme for you.
Horizon Europe 2021 – 2027 and Health
Horizon Europe is the EU’s keystone funding programme for research and innovation with over €95.5 billion budget succeeding Horizon 2020 for the 2021 – 2027 timeline. Horizon Europe’s ambition is to achieve the UN’s SDGs and boosting the EU’s competitiveness and growth while tackling global challenges through collaborations on research and innovation.
Health is among those global challenges that need to be resolved. Health importance was heightened, especially after the 2020 pandemic, with more funds directed towards improving health systems in Europe.
Health is a political priority for Europe embodied in the first strategic plan for 2021-2024 and identified in all four key strategic orientations for EU research and innovation. Additionally, Health Cluster is the first identified cluster and its first Horizon Europe new calls have already been launched. Health Cluster aims to improve and protect the Health and well-being of citizens of all ages by generating new knowledge, developing innovative solutions and integrating where relevant a gender perspective to prevent, diagnose, monitor, treat and cure diseases.
If you are interested in receiving funding for these Horizon Europe new calls for research on Health, you can submit your proposal through the EUcalls innovative platform. To make it easier for you, we have gathered 7 Horizon Europe new calls currently open to receiving your proposal.
7 Horizon Europe New Calls for Research on Health
Title: Safe use and reliable supply of medical radionuclides
Programme: HORIZON-EURATOM-2021-NRT-01-10
Budget: € 4,000,000
Description: Therapeutic nuclear medicine is developing rapidly in oncology. Theranostics – the combination of diagnostics and therapy – is an emerging application of medical isotopes that exploits different properties of radioisotopes. Targeted radionuclide therapy, including alpha and beta therapy, is a promising approach for the treatment of cancer. Several alpha- and beta-emitting isotopes have demonstrated effectiveness in preclinical studies and clinical trials. Theranostic compounds are likely to make a difference to cancer patients in the near future not only through improvements in their quality of life but also in terms of survival rate. Appropriate availability of alpha- and beta-emitting radionuclides must be ensured to treat patients and enable investigation of feasibility of targeted radionuclide therapies.
Deadline: 07/10/2022
Title: Personalised blueprint of chronic inflammation in health-to-disease transition
Programme: HORIZON-HLTH-2022-STAYHLTH-02-01
Budget: € 7,000,000
Description: Personalised approaches for disease prevention seek to determine the predisposition to disease and deliver timely and targeted prevention measures. Understanding the risk factors that trigger the health-to-disease transition is essential for delivering personalised prevention measures or reducing the burden of chronic diseases.
Deadline: 21/04/2022
Programme: HORIZON-HLTH-2022-CARE-08-02
Budget: € 5,000,000
Description: Pre-commercial procurement (PCP) can boost innovation in health care systems, while building the capacity of providers and increasing resilience and preparedness in the context of cross-border public health emergencies. Through the competitive development of a range of breakthrough innovations for a concrete health care challenge, PCP can strengthen the security of the supply chain in the health care sector.
Deadline: 21/04/2022
Programme: HORIZON-CL3-2021-DRS-01-05
Budget: € 8,000,000
Description: The recent COVID-19 crisis has demonstrated that the ability to rapidly identify viruses on scene under a proper quality control/assurance regime is crucial to ensure adequate risk assessment, optimal risk management, and proper counter measures. Consequently, a determining factor is to bring a rapidly deployable diagnostic capacity as close as possible to the crisis area. Considering specific infectious diseases is of paramount importance as also is the possibility to develop scalable capacities for joint multinational intervention.
Deadline: 23/11/2021
Title: Ensured infrastructure resilience in case of Pandemics
Programme: HORIZON-CL3-2021-INFRA-01-02
Budget: € 20,000,000
Description: Pandemics such as the COVID-19 crisis and other health risks have the potential to massively disrupt the functioning of infrastructures and vital societal functions. While this is most evident for the health system, the negative impacts reach much further. Resilient infrastructure systems particularly ‘lifeline’ services such as electric power, water and health care are critical for minimising the societal impact of extreme events. It is essential to develop targeted solutions to ensure continuity of operations of different services and supplies, which are also critical to allow for prevention, preparedness and response to pandemics.
Deadline: 23/11/2021
Programme: Cybersecurity - HORIZON-CL3-2021-CS-01-01
Budget: € 21,500,000
Description: This action aims at developing new methodologies, services and tools for accelerating the self-recovery and possible adaptation of the infrastructures and supply chains after an attack. In line with the NIS Directive the focus should be on critical sectors (e.g. energy, transportation, health) as well as telecommunication networks. The proposal should go beyond the state-of-the-art in developing and validating AI-based self-healing, effective business continuity and disaster recovery in real-world scenarios covering two or more business sectors and supporting their private and public actors.
Deadline: 21/10/2021
Title: Medical Technology and Devices: from Lab to Patient
Programme: HORIZON-EIC-2021-TRANSITIONCHALLENGES-01-01
Budget: € 2,500,000
Description: Medical Technology and Devices businesses are facing long and capital-intensive product development cycles, complex regulatory procedures, slow market uptake requiring the support of key opinion leaders and intensive follow-up with early adopters. In addition to a mature technology, a well thought-out and realistic exploitation path with emphasis on achieving market traction as proof of both clinical and market potential of the idea is needed.
Deadline: 22/09/2021
If you are interested in receiving funding for the above Horizon Europe new Calls for research on Health or find partners, you can take advantage of our summer offer for 50% off to all annual standard or Tailored plans until July 31st 2021.
For any inquiries, you can contact us at info@eucalls.net.
